Memon, A.R., Butler, J., O'Riordan, M., Guerin, E., Dimitrov, B.D. and Harty, J.A.
Comparison of Serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment versus no treatment
Journal of Clinical Densitometry, 16, (1), . (doi:10.1016/j.jocd.2012.07.003). (PMID:22959779).
Full text not available from this repository.
Complex pathways affect bone metabolism at the cellular level, and a balance between osteoblast and osteoclast activity is critical to bone remodeling. One of the major pathways affecting bone metabolism is Wnt/?-catenin signaling, and its disturbances lead to a wide range of bone abnormalities. An important antagonist of this pathway is Dickkopf-1 (Dkk1). Higher Dkk1 levels have been associated with increased bone loss due to inhibition of Wnt pathway. Currently, bisphosphonates are the most commonly used agents to treat primary osteoporotic patients. This study demonstrates the effect of bisphosphonates on Dkk1 levels and its correlation with bone mineral density (BMD). Eighty patients with low BMD were recruited and divided into 2 groups of 40 each (bisphosphonate treatment group and control group). The mean Dkk1 level in the treatment group was significantly reduced to 2358.18 vs 3749.80pg/mL in the control group (p<0.001). Pearson correlation coefficient showed negative correlation between Dkk1 and BMD at lumbar spine (r=?0.55) and femoral neck in the control group; however, no such correlation was found in the treatment group (r=?0.05). Hence, bisphosphonate therapy leads to reduction in Dkk1 levels, but it does not correlate with BMD in such patients.
Actions (login required)